DNLIDenali Therapeutics Inc.
$19.46+53% 1Y
$19.46
$13.0552 weeks$26.49
Is the business good?
Watch
1 to watch, 3 without dataMargins compressing. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margin direction, 3 years−1425.9 ptsderived
Operating margin has narrowed over the past few years, profitability per dollar of sales is eroding.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is DNLI?
- Share count, year on year
- +9.3%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2020 | 19% |
| FY2021 | −608% |
| FY2022 | −314% |
| FY2023 | −60% |
Details›
- Free cash flow, trailing twelve months
- −$440M
- Net income, trailing twelve months
- −$511M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.